Does the association with diabetes say more about schizophrenia and its treatment? - The GLUT hypothesis

Medical Hypotheses

Volumn 77, Issue 4, 2011, Pages 529-531

  De Silva, Prasanna N ^a  

^a The Anchorage   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIDIABETIC AGENT; DOPAMINE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLUTAMATE RECEPTOR AGONIST; GLUTAMIC ACID; METFORMIN; NEUROLEPTIC AGENT;

ADOLESCENCE; ARTICLE; BASAL GANGLION; BRAIN FUNCTION; BRAIN METABOLISM; BRAIN PROTECTION; CEREBELLUM; CHILDHOOD; DELUSION; DIABETES MELLITUS; DISEASE ASSOCIATION; EXECUTIVE FUNCTION; GENETIC ASSOCIATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HALLUCINATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LIMBIC CORTEX; LOW BIRTH WEIGHT; NEGATIVE SYNDROME; NEURONAL PRUNING; NONHUMAN; OBESITY; PERINATAL PERIOD; PREFRONTAL CORTEX; PROTEIN LOCALIZATION; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; THALAMUS;

ANIMALS; CLOZAPINE; DIABETES COMPLICATIONS; DOPAMINE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HALOPERIDOL; HUMANS; MICE; MODELS, THEORETICAL; SCHIZOPHRENIA;

EID: 80052626813     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.06.022     Document Type: Article

References (28)

1. Arndt S., Andreasen N.C., Flaum M., et al. A longitudinal study of symptom dimensions in schizophrenia. Arch Gen Psychiatry 1995, 52:352-360.
2. 'The history of sugar'. http://www.britishsugar.co.uk.
3. Kooy F.H. Hyperglycemia in metal disorders. Brain 1919, 42:214-289.
4. Kirkpatric B., et al. Impaired glucose tolerance in drug naïve schizophrenics. Schizophr Res 2009, 107(2-3):122-127.
5. Mukherjee S., Schnur D.B., Reddy R. Family history of type 2 diabetes in schizophrenic patients (letter). Lancet 1989, 1:495.
6. Spelman L.M., Walsh P.I., Sharifi P.I., et al. Impaired glucose tolerance in first episode drug naïve patients with schizophrenia. Diabet Med 2007, 24:481-485.
7. Taylor D., Young C., Mohamed R., et al. Undiagnosed impaired fasting glucose and diabetes mellitus amongst in patients receiving anti psychotic drugs. J Psychopharmacol 2005, 19(2):162-186.
8. Smith H., Kenny-Herbert J., Knowles L. Clozapine induced diabetic keto acidosis. Aust N Z J Psychiatry 1999, 120-121.
9. Dwyer D., Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 2003, 75(2):255-260.
10. Dwyer D.S., Lu X.H., Bradley R.J. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res 2003, 9711:31-39.
11. McDermott E., de Silva P. Impaired neuronal glucose uptake in pathogenesis of schizophrenia - can GLUT 1 and GLUT 3 deficits explain imaging, post mortem and pharmacological findings?. Med Hypotheses 2005, 65:1076-1081.
12. Saykin A.J., Shrasel D.L., Gur R.E., et al. Neuropsychological deficits in neuroleptics naïve patients with first episode schizophrenia. Arch Gen Psychiatry 1994, 51:124-131.
13. Liddle P.F., Friston K.J., Frith C.D., et al. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992, 160:179-186.
14. De Lisi L.E. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr Bull 2008, 34(2):312-321.
15. Rifkin L., Lewis S., Jones P., Toone B., Murray R. Low birth weight and schizophrenia. Br J Psychiatry 1994, 165:357-362.
16. Rapoport J.L., Giedd J.N., et al. Progressive cortical change in childhood schizophrenia. Arch Gen Psychiatry 1999, 56(7):649-654.
17. Harrison P.J. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 1999, 122:593-624.
18. Murray R.M., Lewis S.W. Is schizophrenia a neurodevelopmental disorder?. Br Med J 1987, 295:681-682.
19. Crow T.J. The two syndrome concept: origins and current status. Schizophr Bull 1985, 11:471-486.
20. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., et al. Modulation of amphetamine induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000, 48:627-640.
21. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148(10):1301-1308.
22. Zhao Y., Fung C., Shin D., et al. Neuronal glucose transporter isoform 3 deficient mice demonstrate features of autism spectrum disorders. Mol Psychiatry 2009, 15:286-299.
23. Gough S.C., O'Donovan M.C. Clustering of metabolic comorbitity in schizophrenia: a genetic contribution?. J Psychopharmacol 2005, 19:47-55.
24. Girgis R.R., Javich J.A., Lieberman J.A. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signalling pathway. Mol Psychiatry 2008, 1-12.
25. Lieberman J.A., Tollefson G.D., Charles C., et al. Antipsychotic drug effects on brain morphology in first episode psychosis. Arch Gen Psychiatry 2005, 62:361-370.
26. Wu R., et al. Metformin addition attenuates Olanzapine induced weight gain in drug naive first episode schizophrenia patients: a double blind, placebo controlled study. Am J Psychiatry 2008, 165:352-358.
27. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001, 158:136-137.
28. Matos M., Augusto E., et al. Amyloid beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen activated protein kinase cascades. Neurosciences 2008, 156(4):898-910.